Work

What is the Most Cost-Effective Strategy for Treating Chronic Myeloid Leukemia After Imatinib Loses Patent Exclusivity in Europe?

Year: 2014

Type: article

Source: Value in Health

DOI: 10.1016/j.jval.2014.08.2284

Authors: W.V. Padula, R. Conti, R. Larson

Institution: University of Chicago

Language: English

Topic: Health Systems, Economic Evaluations, Quality of Life

Subfield: Economics and Econometrics

Field: Economics, Econometrics and Finance

Domain: Social Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W2086871637

FWCI: 2.487

Cites:

Cited by: 6

Related to: 10